Shots:

• BiomX will generate metagenomic data of gut microbiome samples obtained from IBD patients with the focus of identifying biomarkers using the XMarker platform
• Boehringer Ingelheim gets an option to negotiate an exclusive right to biomarkers discovered under the collaboration.
• The XMarker platform supports the phage therapy for IBD- BX002- via analysis of real-world metagenomic patient data. The BiomX will continue to advance the therapy in P-Ia study independently- which is expected to be initiated in Q3’20

­ Ref: PRNewswire | Image: Downriver Gastroenterology- PC